Urologix Inc (ULGX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2015

Urologix Inc

CIK: 882873 Ticker: ULGX




May 12, 2015

For Immediate Release


Urologix Reports Third Quarter Fiscal Year 2015 Results


Recent Quarter Results


Revenue $2.8 Million
Ending cash balances, including restricted cash of $532,000
$2.8 million owed under the Prostiva license and Medtronic promissory note remains past due
Cost-effectiveness of Urologix products being presented at 2015 American Urological Association annual meeting


MINNEAPOLIS — May 12, 2015 — Urologix, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal year 2015 third quarter ended March 31, 2015.


Third quarter revenue totaled $2.8 million, a decrease of 9% from the second quarter of fiscal year 2015 and down 17% compared to the third quarter of the prior fiscal year 2014. The sequential and year-over-year decrease in revenue was driven by a decrease in both Cooled ThermoTherapy and Prostiva® unit sales. The year-over-year decline was partially due to changes from our restructuring launched in April 2014.


“The entire team did an excellent job of managing our cash utilization in what was a challenging quarter for top line results. Our minimal cash utilization was predominantly due to changes in working capital. In addition, we are proud to have our technologies highlighted in a podium session at this week’s American Urological Association annual meeting. The presentation demonstrates our compelling combination of low costs and favorable outcomes for patients, providers and payers,” stated Greg Fluet, Chief Executive Officer. “We remain focused on improving cash flows from operations and pursuing alternatives to address the obligations to our creditor.”


Total operating expense was $1.5 million for the third quarter of fiscal year 2015, a 37% reduction compared to $2.3 million of operating expense for the third quarter of fiscal year 2014. The decrease in operating expenses compared to the prior year period is primarily a result of the 50% reduction in sales and marketing expense associated with the strategic reorganization the Company implemented in the latter half of fiscal year 2014. Operating expenses were 8% lower compared to the second quarter of fiscal year 2015, which were $1.6 million.




The Company reduced its net loss by 79% to a net loss of $349,000, or $0.02 per diluted share, for the third quarter of fiscal year 2015, compared to a net loss of $1.7 million, or $0.08 per diluted share, in the third quarter of fiscal year 2014. The net loss per diluted share was consistent with the second quarter of fiscal year 2015, which was also $0.02 per diluted share.


As of March 31, 2015, the Company’s cash balances totaled $532,000, including $40,000 of restricted cash, compared to $570,000 as of December 31, 2014, reflecting cash utilization of $38,000 for the quarter. This decrease in the Company’s cash balances compares to a decrease in the third quarter of the prior year of $451,000. The significant improvement in the Company’s cash utilization compared to the prior year was driven by the positive impact of our previously discussed organizational changes at the end of the 2014 fiscal year. The Company’s cash utilization in the third quarter of both fiscal years 2014 and 2015 reflects non-payment of the annual royalty and license amounts due to Medtronic in those periods and, for the third quarter of fiscal year 2015, also reflects non-payment of promissory note amounts due to Medtronic.


The gross profit for the third quarter of fiscal year 2015 was $1.3 million, or 47% of revenue, compared to $849,000, or 25% of revenue, in the third quarter of prior year fiscal 2014. The fiscal year 2014 third quarter costs of goods sold included a $739,000 charge for slow moving Prostiva capital equipment inventory. The gross margin was relatively consistent with the second quarter of fiscal year 2015, with gross profit of $1.5 million, or 48% of revenue, in the second quarter of fiscal year 2015.


Regarding Amounts Due to Medtronic


As of March 31, 2015, there was a total of $2.8 million due to Medtronic, which amounts currently remain unpaid. This amount consists of the first payment of $1.3 million on the $5.3 million promissory note to Medtronic which was due March 31, 2015 and $1.5 million of royalties and other fees due under the Prostiva license. Royalty payments currently due and unpaid are included in short-term deferred acquisition payments under current liabilities as of March 31, 2015. Because of the non-payment under the promissory note, there existed an event of default as of April 14, 2015 under the note entitling Medtronic to declare all outstanding obligations under the promissory note immediately due and payable. The Company’s ability to continue as a going concern is dependent upon its ability to address the outstanding indebtedness to Medtronic. The Company believes that this debt is most likely to be addressed through strategic alternatives, which the Company is diligently pursuing. The Company’s failure to address its indebtedness to Medtronic to Medtronic’s satisfaction may result in seizure by Medtronic of the assets that secure the Company’s indebtedness, loss of control of the Company’s business, bankruptcy or cessation of the business.




Earnings Call Information


Urologix will host a conference call with the financial community to discuss fiscal year 2015 third quarter results on Tuesday, May 12, 2015 at 4:00 p.m. CDT. To listen to the call, please dial 1-877-359-9508 and enter the conference ID 42703418 at least 10 minutes prior to the call. A live webcast of the call will be available through the investor relations section of the Company’s website at and available for replay approximately two hours after the completion of the call.



About Urologix


Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’s Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.


If you’d like more information on this topic, please contact Scott Madson at (763) 475-1400 or or to learn more about Urologix and its products and services, visit their website at


The Urologix, Inc. logo is available at


Forward Looking Statements


This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, the Company’s ability to address its indebtedness to Medtronic through one or more strategic alternatives (which may not ultimately be realized), the sufficiency of the Company’s cash balances to sustain day-to-day operations for any particular length of time, the Company’s ability to continue as a going concern particularly in light of the remedies available to Medtronic relating to the Company’s failure to pay amounts owed, the effectiveness of the Company’s sales and marketing strategies and the impact of the Company’s strategic restructurings, the Company’s future revenue and operating performance, or about the development and marketing of products. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014 and other documents filed with the Securities and Exchange Commission.


Urologix Media Contact Urologix Investor Relations Contact
Susan Overby Scott Madson
(763) 745-1540 (763) 475-1400





Urologix, Inc.
Statements of Operations
(Unaudited, in thousands, except per-share data)


   Three Months Ended
March 31,
   Nine Months Ended
March 31,
   2015   2014   2015   2014 
Sales  $2,796   $3,356   $8,896   $10,941 
Cost of goods sold   1,485    2,507    4,659    6,431 
Gross profit   1,311    849    4,237    4,510 
Costs and expenses:                    
Sales and marketing   657    1,313    2,196    4,839 
General and administrative   449    527    1,404    1,773 
Research and development   298    408    969    1,281 
Change in value of acquisition consideration       (12)       (105)
Medical device tax   44    52    140    172 
Amortization expense   16    28    56    72 
Total costs and expenses   1,464    2,316    4,765    8,032 
Operating loss   (153)   (1,467)   (528)   (3,522)
Interest expense   (190)   (178)   (594)   (516)
Foreign currency exchange gain/(loss)   (6)   (1)   (12)   1 
Loss before income taxes   (349)   (1,646)   (1,134)   (4,037)
Income tax expense       18    9    46 
Net loss  $(349)  $(1,664)  $(1,143)  $(4,083)
Net loss per common share—basic  $(0.02)  $(0.08)  $(0.05)  $(0.19)
Net loss per common share—diluted  $(0.02)  $(0.08)  $(0.05)  $(0.19)
Weighted average number of common shares
   21,838    21,326    21,701    21,195 
Weighted average number of common shares
   21,838    21,326    21,701    21,195 





Urologix, Inc.
Balance Sheets
( in thousands)


   March 31,
   June 30,
Current assets:          
Cash  $492   $718 
Restricted cash   40     
Accounts receivable, net   1,392    1,502 
Inventories   1,319    1,397 
Prepaids and other current assets   160    63 
Total current assets   3,403    3,680 
Property and equipment:          
Property and equipment   12,144    12,162 
Less accumulated depreciation   (11,853)   (11,691)
Property and equipment, net   291    471 
Other intangible assets, net   1,230    1,370 
Long-term inventories   94    141 
Other assets   5    5 
Total assets  $5,023   $5,667 
Current liabilities:          
Accounts payable  $708   $892 
Accrued compensation   371    487 
Short-term deferred acquisition payment   2,044    1,339 
Current portion of long-term debt   1,795    747 
Interest Payable   634    322 
Other accrued expenses   577    505 
Total current liabilities   6,129    4,292 
Long-term deferred acquisition payment   3,412    3,730 
Long-term debt   3,537    4,586 
Other accrued liabilities   8    36 
Total liabilities   13,086    12,644 
Common stock   213    209 
Additional paid-in capital   119,493    119,440 
Accumulated deficit   (127,769)   (126,626)
Total shareholders’(deficit)   (8,063)   (6,977)
Total liabilities and shareholders’(deficit)  $5,023   $5,667 




Urologix, Inc.
Condensed Statements of Cash Flows
(Unaudited, in thousands)


   Nine Months Ended
March 31,
   2015   2014 
Operating Activities:          
Net loss  $(1,143)  $(4,083)
Adjustments to reconcile net loss to net cash used for operating activities:          
Depreciation and amortization   361    447 
Employee stock-based compensation expense   53    169 
Provision for bad debts   20    (7)
   Prostiva inventory reserve       739 
Loss on disposal of assets   2    3 
Accretion expense on deferred acquisition payments   387    334 
Net adjustment to acquisition consideration       (105)
Deferred income taxes       27 
Change in operating items, net of acquisition:          
Accounts receivable   90    342 
Inventories   99    336 
Prepaids and other assets   (97)   (86)
Accounts payable   (184)   387 
Accrued expenses and deferred income   (72)   (187)
Interest payable   312    245 
Net cash used in operating activities   (172)   (1,439)
Investing Activities:          
Purchase of property and equipment   (8)   (28)
Purchases of intellectual property   (15)   (7)
Proceeds from sale of property and equipment   9     
Cash restricted for collateral   (40)    
Net cash used for investing activities   (54)   (35)
Net decrease in cash    (226)   (1,474)
Beginning of period   718    2,290 
End of period  $492   $816 
Supplemental cash-flow information          
Income taxes paid during the period  $9   $27 
Net amount of inventory transferred to property and equipment  $26   $46 




The following information was filed by Urologix Inc (ULGX) on Wednesday, May 13, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Urologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Urologix Inc.


Assess how Urologix Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Urologix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheets
Condensed Balance Sheets (parenthetical)
Condensed Statements Of Cash Flows
Condensed Statements Of Operations
Basic And Diluted Loss Per Share
Basic And Diluted Loss Per Share (details)
Basis Of Presentation
Commitments And Contingencies
Fair Value Measurements
Fair Value Measurements (narrative) (details)
Fair Value Measurements (reconciliation Of Contingent Consideration Liability) (details)
Fair Value Measurements (tables)
Financing Arrangements
Financing Arrangements (details)
Income Taxes
Income Taxes (narrative) (details)
Intangible Assets
Intangible Assets (future Amortization Expense Related To Net Carrying Amount Of Intangible Assets) (details)
Intangible Assets (narrative) (details)
Intangible Assets (schedule Of Intangible Assets) (details)
Intangible Assets (tables)
Inventories (narrative) (details)
Inventories (schedule Of Inventories) (details)
Inventories (tables)
Liquidity (details)
Recently Issued Accounting Pronouncements
Restricted Cash
Stock-based Compensation
Stock-based Compensation (amounts Recognized In Financial Statements Related To Stock-based Compensation) (details)
Stock-based Compensation (assumptions Used To Estimate Fair Value Of Options Granted) (details)
Stock-based Compensation (narrative) (details)
Stock-based Compensation (summary Of Non-vested Restricted Stock Activity) (details)
Stock-based Compensation (summary Of Stock Option Activity) (details)
Stock-based Compensation (tables)
Subsequent Event
Subsequent Event (narrative) (details)
Use Of Estimates
Warranty (details)
Warranty (tables)

Material Contracts, Statements, Certifications & more

Urologix Inc provided additional information to their SEC Filing as exhibits

Ticker: ULGX
CIK: 882873
Form Type: 10-Q Quarterly Report
Accession Number: 0000897101-15-000655
Submitted to the SEC: Thu May 14 2015 4:05:52 PM EST
Accepted by the SEC: Thu May 14 2015
Period: Tuesday, March 31, 2015
Industry: Electromedical And Electrotherapeutic Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: